Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Arcadia Biosciences (RKDA) EPS (Weighted Average and Diluted) (2020 - 2025)

Arcadia Biosciences' EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at -$0.98 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 66.89% year-over-year to -$0.98; the TTM value through Dec 2025 reached -$1.72, up 45.74%, while the annual FY2025 figure was -$1.71, 46.06% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.98 in Q4 2025 per RKDA's latest filing, down from $0.62 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $5.01 in Q4 2023 to a low of -$27.3 in Q4 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$3.13, with a median of -$0.92 recorded in 2025.
  • Peak YoY movement for EPS (Weighted Average and Diluted): tumbled 7454.55% in 2022, then soared 371.43% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$27.3 in 2021, then soared by 83.08% to -$4.62 in 2022, then soared by 208.44% to $5.01 in 2023, then plummeted by 159.08% to -$2.96 in 2024, then skyrocketed by 66.89% to -$0.98 in 2025.
  • Per Business Quant, the three most recent readings for RKDA's EPS (Weighted Average and Diluted) are -$0.98 (Q4 2025), $0.62 (Q3 2025), and -$3.26 (Q2 2025).